Author:
Sims Terran W.,Gray Mikel
Publisher
Springer International Publishing
Reference20 articles.
1. American Facts and Figures 2019.
https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancerfacts-and-figures/2019/cancer-facts-and-figures-2019.pdf
accessed July 13,2020.
2. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsk PC, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294:433–9.
3. Zaorsky NG, Raj GV, Trabulsi EJ, Lin J, Den RB. The dilemma of a rising prostate-specific antigen level after local therapy: what are our options? Semin Oncol. 2013;40(3):322–36.
4. Roach M 3rd, Hanks G, Thames H Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65(4):965–74.
5. Boorjian SA, Karnes RJ, Viterbo R, et al. Long–term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer. 2011;117(13):2883–91.